Bros. Advisors Lp Baker Sells 260,600 Shares of Bellicum Pharmaceuticals, Inc. (BLCM) Stock

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $8.63, for a total value of $2,248,978.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Bros. Advisors Lp Baker also recently made the following trade(s):

  • On Friday, January 19th, Bros. Advisors Lp Baker sold 880,735 shares of Bellicum Pharmaceuticals stock. The shares were sold at an average price of $8.20, for a total value of $7,222,027.00.

Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) opened at $7.80 on Friday. Bellicum Pharmaceuticals, Inc. has a fifty-two week low of $7.41 and a fifty-two week high of $15.55. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $253.00, a P/E ratio of -2.61 and a beta of 1.18.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.03. The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. During the same quarter in the prior year, the business earned ($0.66) EPS. The firm’s revenue for the quarter was up 18.2% compared to the same quarter last year. sell-side analysts forecast that Bellicum Pharmaceuticals, Inc. will post -2.93 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Bellicum Pharmaceuticals by 13.6% in the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock valued at $14,092,000 after purchasing an additional 144,854 shares in the last quarter. State Street Corp lifted its holdings in shares of Bellicum Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock valued at $4,872,000 after purchasing an additional 59,321 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Bellicum Pharmaceuticals in the third quarter valued at approximately $4,723,000. Northern Trust Corp lifted its holdings in shares of Bellicum Pharmaceuticals by 29.5% in the second quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock valued at $3,989,000 after purchasing an additional 77,760 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Bellicum Pharmaceuticals by 223.5% in the second quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock valued at $1,612,000 after purchasing an additional 95,336 shares in the last quarter. Institutional investors own 55.28% of the company’s stock.

A number of equities research analysts have commented on BLCM shares. Zacks Investment Research raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Raymond James Financial reissued a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, December 12th. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $23.33.

ILLEGAL ACTIVITY NOTICE: “Bros. Advisors Lp Baker Sells 260,600 Shares of Bellicum Pharmaceuticals, Inc. (BLCM) Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/21/bros-advisors-lp-baker-sells-260600-shares-of-bellicum-pharmaceuticals-inc-blcm-stock.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Insider Buying and Selling by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply